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Abstract
AIM
To evaluate brain metastases volume control capabilities 
of stereotactic radiosurgery (SRS) through serial 
magnetic resonance (MR) imaging follow-up. 
METHODS
MR examinations of 54 brain metastases in 31 patients 
before and after SRS were reviewed. Patients were 
included in this study if they had a pre-treatment MR 
examination and serial follow-up MR examinations at 6 
wk, 9 wk, 12 wk, and 12 mo after SRS. The metastasis 
volume change was categorized at each follow-up as 
increased (> 20% of the initial volume), stable (± 20% 
of the initial volume) or decreased (< 20% of the initial 
volume). 
RESULTS 
A local tumor control with a significant (P  < 0.05) 
volume decrease was observed in 25 metastases at 
6-wk follow-up. Not significant volume change was 
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observed in 23 metastases and a significant volume 
increase was observed in 6 metastases. At 9-wk follow-
up, 15 out of 25 metastases that decreased in size at 
6 wk had a transient tumor volume increase, followed 
by tumor regression at 12 wk. At 12-wk follow-up there 
was a significant reduction in volume in 45 metastases, 
and a significant volume increase in 4 metastases. At 
12-mo follow-up, 19 metastases increased significantly 
in size (up to 41% of the initial volume). Volume tumor 
reduction was correlated to histopathologic subtype.
CONCLUSION
SRS provided an effective local brain metastases volume 
control that was demonstrated at follow-up MR imaging.
Key words: Brain metastases; Stereotactic radiosurgery; 
Magnetic resonance imaging; Pseudo-progression; 
Radiation therapy
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: Stereotactic radiosurgery (SRS) provided 
an effective long-term local volume control of brain 
metastases during 12-mo magnetic resonance (MR) 
imaging follow-up. A significant reduction of the tumor 
volume by 6 wk post-SRS was associated with long-
term volume control suggesting that the timing for MR 
imaging follow-up at 6 wk, 9 wk, 12 wk and 12 mo after 
SRS, could be considered the most effective to provide 
useful information to make the best treatment decisions. 
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INTRODUCTION
Brain metastases account for 20%-40% of adult 
cancer and affect survival and quality of life[1]. The two 
most commonly used treatments for brain metastases 
are whole-brain radiation therapy and stereotactic 
radiosurgery (SRS), which extend survival from 3 mo to 
5 mo and from 7 mo to 13 mo, respectively, depending 
on tumor type. Surgical resection remains a valuable 
approach for patients with larger symptomatic meta-
static tumors[2]. 
SRS is an increasingly used procedure for the 
treatment of primary and metastatic intracranial brain 
tumors. Indications include patients with few, well-
defined, and small intracranial brain tumors. In SRS, 
radiations are directly delivered into a brain tumor, 
thus reducing radiation dose of surrounding normal 
brain tissue and side effects such as neurotoxicity, skin 
damage, nausea and vomiting[3-5]. The damage to the 
peritumoral brain is further reduced by a step dose 
gradient at the target periphery of the tumor[3]. 
The objectives of SRS include local tumor control, 
defined as the absence of a substantial (< 25%) 
increase in tumor volume at follow-up magnetic reson-
ance (MR) imaging, improved quality of life, and pro-
longed survival[6,8]. Metastatic lesions are particularly 
well-suited for the treatment with SRS because they are 
usually small (< 3 cm), well-circumscribed, and have 
well-defined margins[6]. 
Studies have demonstrated that SRS is an effective 
alternative to traditional surgical resection and whole 
brain radiotherapy in patients with single or few well-
defined brain metastases[1,7-9]. 
Knowledge of natural history of brain metastases 
treated with SRS is crucial to prevent management 
dilemmas, and reduce patient anxiety. For instance, 
radiation toxicity can sometimes cause a pseudo-
progression of brain metastases, which usually resolves 
with time[1,7,9,10].
The purpose of this study is to evaluate volume 
tumor control capabilities of SRS in the treatment of 
brain metastases trough serial MR imaging follow-up. 
MATERIALS AND METHODS
Patient population
This was a retrospective study approved by the 
Institutional Review Board of our institution. All patients 
were referenced with the diagnosis of brain metastases 
and were treated with Gamma Knife-SRS (Leksell 
Gamma Knife, model 4C, GammaPlan 5.3; Elekta 
Instruments, Stockholm, Sweden) at a single academic 
medical center from January 2015 to January 2016. All 
patients had given written consent for this retrospective 
study. Patients were included in this study if they had 
a pre-treatment MR examination and serial follow-up 
MR examinations within 6 wk, 9 wk, 12 wk, and 12 mo 
post-SRS.
Patients were excluded if SRS was performed 
for consolidation to a surgical resection bed only. 
Additionally, patients in whom lesions required salvage 
surgery due to symptomatic local failure, were 
excluded.
The SRS dose delivered to the tumor margins 
ranged from 18 to 24 Gy prescribed to the 40%-70% 
isodose surface. Radioresistant tumors (melanoma, 
renal cancer) received a median marginal dose of 23.7 
Gy (range, 20-24 Gy), and radiosensitive tumors (lung 
and, breast cancer) received a median marginal dose of 
21.3 Gy (range, 18-24 Gy). 
There was a total of 31 patients (14 men, 17 
women; age: 32-77 years; mean age, 51, 5 years) that 
underwent serial MR imaging examinations at 6 wk, 9 
wk, 12 wk, and 12 mo after SRS. 
Brain metastases were confirmed by pathology. 
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There were 54 brain metastases: Non-small cell 
lung carcinoma n = 19 (36%), breast carcinoma n 
= 16 (29%), renal cell carcinoma n = 9 (16%), and 
melanoma n = 10 (19%). Patient population and 
primary cancer types are summarized in Table 1.
MR imaging
All MR examinations were performed with a 1.5T MR 
scanner (Signa Excite, GE Medical Systems, Milwaukee, 
United States). MR imaging protocol included axial 
and sagittal fast spin-echo (FSE) T2W [5100/110 (TR/
TE)] images, axial fluid-attenuated inversion-recovery 
(FLAIR) [8000/140/2400 (TR/TE/TI)] images, along with 
axial, sagittal, and coronal non-enhanced and contrast-
enhanced (0.1 mmol/Kg gadobutrol - Gadovist, Bayer, 
Germany) FSE T1W [650/15 (TR/TE)] images with a 
FOV of 22 cm, matrix 512 × 512, slice thickness 5 mm, 
intersection gap 1 mm, number of excitations 2. Follow-
up MR examinations were performed at 6 wk, 9 wk, 12 
wk, and 12 mo post-SRS.
Volume change analysis
Two experienced neuroradiologists evaluated in con-
sensus the maximum enhancing metastasis volume 
measured in 3 orthogonal planes at initial MR examina-
tions and at each follow-up. Tumor volume was calcu-
lated according to the following formula: Volume 
= length × width × height/2 as reported in other 
studies[7]. Metastases of at least 0.5 cm3 were included. 
Metastasis volume change was categorized at each 
follow-up as increased (> 20% of the initial volume), 
stable (± 20% of the initial volume) or decreased (< 
20% of the initial volume). This criteria was chosen 
taking in account a measurement error of 20%, as 
there are no validated categorization schemes for tumor 
response.
Statistical analysis
Statistical analysis was performed using the statistical 
software package SPSS (SPSS, Chicago, Ill). The 
Wilcoxon signed-rank test for continuous variables was 
used to evaluate the significance of volume change. 
A multivariate logistic regression analysis was used to 
determine the correlation between histopathology and 
volume changes. A P value of < 0.05 was considered 
statistically significant.
RESULTS
Primary cancer types and effective time point for MR 
imaging follow-up to identify significant phases of 
the response to the SRS therapy are summarized in 
Table 2. At 6-wk follow-up, a local tumor control with a 
significant volume decrease up of 63% was observed 
in 25 brain metastases (46%) (12 non-small cell lung 
carcinoma, 11 breast carcinoma, 1 renal cell carcinoma, 
1 melanoma). No significant volume change was 
observed in 23 metastases (43%) (6 non-small cell lung 
carcinoma, 5 breast carcinoma, 7 renal cell carcinoma, 
5 melanoma), and a significant volume increase was 
observed in 6 metastases (11%) (1 non-small cell lung 
carcinoma, 1 renal cell carcinoma, 4 melanoma). 
At 9-wk follow-up, 15 out of 25 radiosensitive brain 
metastases (28% of the total lesions) (8 non-small cell 
lung cancer, 7 breast metastases) that decreased in size 
at 6 wk had a transient tumor volume increase, followed 
by tumor regression at 12 wk with no clinical symptoms 
(pseudo-progression) (Figure 1). 
At 12-wk follow-up, there was a significant reduction 
in volume in 45 metastases (18 non-small cell lung 
carcinoma, 14 breast carcinoma, 7 renal cell carcinoma, 
6 melanoma), no significant volume change in 5 
metastases (1 non-small cell lung carcinoma, 1 breast 
carcinoma, 1 renal cell carcinoma, 2 melanoma), and 
a significant volume increase in 4 metastases (1 breast 
carcinoma, 1 renal cell carcinoma, 2 melanoma). 
At 12-mo follow-up, 19 (35%) metastases increased 
(true-progression) significantly in size (up to 41% of the 
initial volume) (1 non-small cell lung cancer, 4 breast 
cancer, 6 renal cell carcinoma, 8 melanoma) (Figure 2). 
The logistic regression analysis showed that volume 
tumor reduction correlates to histopathologic subtype: 
non-small cell lung carcinoma had a significant reduction 
of 38% of its initial volume; breast carcinoma had a 
significant reduction of 41% of its initial volume; renal 
cell carcinoma had a significant reduction of 14% of its 
initial volume; melanoma had a significant reduction of 
8% of its initial volume. Thus, higher tumor reduction 
was observed in the radiation sensitive carcinomas 
(breast and non-small cell lung carcinomas). 
Moreover, we evaluated the volume tumor variation 
of breast, non-small cell lung cancer, melanoma, and 
renal cell carcinoma metastases at 6 wk, 9 wk, 12 wk, 
and 12 mo post-SRS. Our results show that response 
categorization differences among these 4 primary types 
were not statistically significant, however melanoma 
and renal cell carcinoma metastases had less robust 
volume reduction than non-small cell lung cancer or 
breast metastases. 
Temporary or permanent clinical complications were 
evaluated during 12 mo follow-up of these patients. 
Transient headache related to intracranial edema was 
noted in 10 patients, with nausea (5 patients) and arm 
or leg weakness (2 patients). Permanent neurologic 
  No. of 
  patients















  7 5 men - 2 
women
55-77 Renal cell 
carcinoma
9 (16)
  4 1 men - 3 
women
32-65 Melanoma 10 (19)
Table 1  Patient population and primary cancer types
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deficits were noted in 6 patients. 
DISCUSSION
Our results suggest that a significant early reduction 
of tumor volume is associated with a good long-
term volume tumor control as reported in previous 
studies[6,7,10-14]. Conversely, increased tumor volume at 
6-wk follow-up has a higher probability of a final increase 
in lesion size, thus in a poor tumor volume control. 
Transient volume growth at 9-wk follow-up occurred 
in 15 radiosensitive brain metastases (8 non-small cell 
lung cancer, 7 breast metastases) (28% of the total 
lesions), followed by tumor regression at 12 wk with no 
A B
C D
Figure 1  Follow-up axial enhanced T1-weighted magnetic 
resonance images of a brain metastasis from breast carcinoma 
treated with stereotactic radiosurgery in a 60-year-old woman. 
A: Pre stereotactic radiosurgery (SRS) magnetic resonance (MR) 
image; B: Initial follow-up MR image at 6 wk after SRS demonstrating 
an initial volume reduction; C: Follow-up MR image at 9 wk after SRS 
demonstrating a transient volume increase (pseudo-progression); D: 
Follow-up MR image at 12 wk demonstrating a final volume reduction. 
A B
C D
Figure 2  Follow-up axial enhanced T1-weighted magnetic 
resonance images of a lung carcinoma metastatic to the right cere-
bellum treated with stereotactic radiosurgery. A: Pre stereotactic 
radiosurgery (SRS) magnetic resonance (MR) image; B: Initial follow-up 
MR image at 6 wk after SRS demonstrating an initial volume reduction; 
C: Follow-up MR image at 9 wk demonstrating volume increase (true-
progression); D: Follow-up MR image at 12 wk with final volume 
increase.
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clinical symptoms (Figure 1 and Table 2). This transient 
growth must be careful interpreted as it could be 
misinterpreted as tumor recurrence, whereas it should 
be interpreted as a pseudo-progression[7]. 
The histopathology of pseudo-progression is probably 
related to treatment-induced tumor inflammation and 
necrosis[7,10-13]. Tumor volume variation trend in our 
series demonstrates that melanoma and renal cell 
carcinoma metastases showed less volume reduction 
than non-small cell lung cancer or breast metastases. 
However, response categorization differences among 
these 4 primary types were not statistically significant, 
thus suggesting that the most effective timing for MR 
imaging follow-up, regardless the type of primary 
tumor, could be considered at 6 wk, 9 wk, 12 wk and 
12 mo after SRS.
The observation that a small percentage of lesions 
may undergo a transient volume increase indicate that 
initial lesion growth does not necessary preclude local 
volume control. Conversely, there were a low number 
of metastases that exhibited initial volume growth and 
continued to grow with no volume control during SRS 
(Figure 2).
SRS has become the standard procedure for the 
treatment of brain metastases as it allows a longer 
survival and higher local control rates compared to 
whole-brain radiation therapy[6,7,9,14]. Compared to 
surgical resection, SRS is associated to lower morbidity 
and decrease cost[1]. 
To summarize, SRS is effective in treating brain 
metastases regardless of their histology, including those 
that are radio-resistant to conventional whole-brain 
radiation therapy, such as metastases that originates 
from melanoma and renal cell carcinoma.
Although initial consistent tumor volume reduction 
after SRS is predictive of long term volume control, 
initial tumor growth does not necessarily indicate 
tumor progression but radiation-induced inflammation 
and necrosis (pseudo-progression) and it should be 
taken into account to avoid to be misinterpreted as a 
recurrence. 
Limitations
This study was a retrospective, single-institution study 
with a relative small size population and these factors 
could be considered limitations. 
To prevent potential inaccuracies in the volume 
measurement of the intracranial lesion, we excluded 
lesions with an initial tumor volume of less than 0.5 cm3 
and a 20% cutoff for volume response categorization 
was chosen. 
In conclusion, effective long-term SRS local volume 
control of brain metastases can be demonstrated at 12 
mo follow-up. Significant tumor volume reduction by 
6 wk post-SRS was associated with long-term volume 
control suggesting that the timing for MR imaging 
follow-up at 6 wk, 9 wk, 12 wk and 12 mo after SRS, 
could be considered the most effective to provide useful 
information to make the best treatment decisions. 
Although it is necessary to validate these results in a 
larger, prospective series, the results are encouraging 
that an early local volume reduction after SRS is 




Brain metastases account for 20% to 40% of adult cancer and affect both 
survival and quality of life. Brain metastases volume reduction is associated 
with significant local control of the lesions and prolongation of patient’s survival. 
Stereotactic radiosurgery (SRS) is an increasingly used procedure for the 
treatment of primary and metastatic intracranial brain tumors to achieve local 
volume reduction. 
Research frontiers
Volume tumor control capabilities of SRS in the treatment of brain metastases 
is an important factor for post-treatment decision making and delivery salvage 
therapy. 
Innovations and breakthroughs
Volume tumor control capabilities of SRS could be demonstrated trough serial 
magnetic resonance (MR) imaging follow-up. Accurate determination of the 
timing for MR imaging follow-up is crucial for decision making and delivery timely 
salvage therapy. 
Applications
Serial MR imaging follow-up at 6 wk, 9 wk, 12 wk, and 12 mo is the most 
effective timing to demonstrate volume reduction of brain metastases after SRS. 
The information derived from serial MR imaging follow-up could affect clinical 
  Primary cancer type No. of lesions %4 Reduced in 
size at 6 wk1
%4 Pseudo-progression 
(9 wk)2
%4 True-progression (12 mo)3 %4
  Non-small cell lung 
  carcinoma
19 36 12 22   8 15   1   2
  Breast carcinoma  16 29 11 20   7 13   4   7
  Renal cell carcinoma   9 16   1   2   0   0   6 11
  Melanoma 10 19   1   2   0   0   8 15
  Total 54 100 25 46 15 28 19 35
Table 2  Primary cancer types and effective time point for magnetic resonance imaging follow-up to provide useful information for 
the treatment decision
1Number of lesions reduced in size at 6-wk follow-up; 2Number of lesions that presented a transient volume growth (pseudo-progression) at 9-wk follow-
up; 3Number of lesions that presented final volume growth (true-progression) at 12-mo follow-up; 4Percentage of lesions computed over the total number of 
lesions (n = 54).
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management and improve survival of these patients.
Terminology
SRS is a procedure for the treatment of primary and metastatic intracranial 
brain tumors. Indications include patients with few, well-defined, and small 
intracranial brain tumors. In SRS, radiations are directly delivered into a brain 
tumor, thus reducing radiation dose of surrounding normal brain tissue and side 
effects such as neurotoxicity, skin damage, nausea and vomiting. The damage 
to the peritumoral brain is further reduced by a step dose gradient at the target 
periphery of the tumor. The objectives of SRS include local tumor control, 
defined as the absence of a substantial (< 25%) increase in tumor volume at 
follow-up MR imaging, improved quality of life, and prolonged survival. 
Peer-review
This study is interesting. However the manuscript would be of higher value to the 
reader if the manuscript focuses on the pseudo-progression period, that period 
is confusing for the practicing physician and can lead to misinterpretation and 
additional or changes in treatment strategies. 
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